ZOVIRAX 400 TABLET

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Koupit nyní

Aktivní složka:

ACYCLOVIR

Dostupné s:

GLAXOSMITHKLINE INC

ATC kód:

J05AB01

INN (Mezinárodní Name):

ACYCLOVIR

Dávkování:

400MG

Léková forma:

TABLET

Složení:

ACYCLOVIR 400MG

Podání:

ORAL

Jednotky v balení:

56

Druh předpisu:

Prescription

Terapeutické oblasti:

NUCLEOSIDES AND NUCLEOTIDES

Přehled produktů:

Active ingredient group (AIG) number: 0115506004; AHFS:

Stav Autorizace:

CANCELLED POST MARKET

Datum autorizace:

2014-02-20

Charakteristika produktu

                                _2008-09-10/131-prisitne-english-zovirax.doc _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
ZOVIRAX
®
Acyclovir Oral Suspension USP, 200 mg /5 mL
Acyclovir Tablets USP, 200, 400, and 800 mg
Antiviral Agent
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
September 10, 2008
SUBMISSION CONTROL NUMBER: 123012
_©_
_ 2008 GlaxoSmithKline Inc. All Rights Reserved _
_®_
_ ZOVIRAX, WELLSTAT PAC and ZOSTAB PAC are registered trademarks,
GlaxoSmithKline Inc. _
_2008-09-10/131-prisitne-english-zovirax.doc _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND
ADMINISTRATION..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND
STABILITY..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL
INFORMATION..........................
                                
                                Přečtěte si celý dokument
                                
                            

Dokumenty v jiných jazycích

Charakteristika produktu Charakteristika produktu francouzština 10-09-2008

Vyhledávejte upozornění související s tímto produktem

Zobrazit historii dokumentů